Naseema Gangat - Publications, H-index & Citations

Naseema Gangat

mayo clinic

64H指数

775论文数

2.1W被引数

收录论文 318

发表时间

Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients 维奈克拉联合去甲基化药物用于新诊断急性髓系白血病7天、14天、21天及28天疗程：基于ELN和Mayo遗传风险分层的540例患者分析

American Journal of Hematology

IF9.9

2026-09-18

PREAI

Sudhesh Kumar; Momna Warraich; Mahnoor Fatima; Kristen McCullough; Aref Al-Kali; Hassan B. Alkhateeb; Kebede H. Begna; Abhishek A. Mangaonkar; Antoine N. Saliba; Mark R. Litzow; William Hogan; Mithun Shah; Mrinal M. Patnaik; Animesh Pardanani; Talha Badar; James Foran; Jeanne Palmer; Cecilia Arana Yi; Ayalew Tefferi; Naseema Gangat

Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia 356例新诊断急性髓系白血病患者一线维奈克拉联合去甲基化药物治疗失败后的生存影响因素

Blood Cancer Journal

IF11.6

2026-08-17

OAAI

Mahnoor Fatima; Sudhesh Kumar; Momna Warraich; Kristen McCullough; Aref Al-Kali; Hassan B. Alkhateeb; Kebede H. Begna; Abhishek Mangaonkar; Antoine N. Saliba; Mark R. Litzow; William Hogan; Mithun V. Shah; Mrinal M. Patnaik; Animesh Pardanani; Talha Badar; James Foran; Jeanne Palmer; Cecilia Arana Yi; Ayalew Tefferi; Naseema Gangat

Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients 慢性髓系单核细胞白血病患者行异基因干细胞移植与未移植者的风险调整生存比较：梅奥诊所775例连续患者的经验

American Journal of Hematology

IF9.9

2026-07-28

PREAI

Ali Alsugair; Saubia Fathima; Mohammad M. Alhousani; Estefania Gauto Mariotti; Abiola Bolarinwa; Priyansh Faldu; Muhammad Yousuf; Clifford M. Csizmar; James Foran; Abishek A. Mangaonkar; Mark Litzow; Hemant Murthy; Lisa Sproat; Jeanne Palmer; Aasiya Matin; Ernesto Ayala; James Slack; Luis Porrata; Madiha Iqbal; Nandita Khera; Nathan Punwani; Saad Kenderian; Saurabh Chhabra; Kebede H. Begna; Animesh Pardanani; William J. Hogan; Mithun Vinod Shah; Hassan B. Alkhateeb; Naseema Gangat; Mrinal Patnaik; Ayalew Tefferi

Selinexor for myelofibrosis or a drug in search of a disease?塞利尼索用于骨髓纤维化或一种在寻找适应症的药物？

Blood Cancer Journal

IF11.6

2026-07-25

OAAI

Naseema Gangat; Ayalew Tefferi

Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms 新诊断的适合患者急性髓系白血病的2026年治疗算法

Blood Cancer Journal

IF11.6

2026-07-18

OAAI

Naseema Gangat; Farhad Ravandi

Cancer history and second cancer risk in polycythemia vera and essential thrombocythemia 多发性骨髓增殖性肿瘤和原发性血小板增多症中的癌症史与第二癌症风险

Blood Cancer Journal

IF11.6

2026-07-11

OAAI

Giuseppe G. Loscocco; Fnu Aperna; Moazah Iftikhar; Priyansh Faldu; Masooma S. Rana; Amritpal Singh; Tiziano Barbui; Paola Guglielmelli; Alessandro M. Vannucchi; Animesh Pardanani; Naseema Gangat; Ayalew Tefferi

Distinct Longitudinal Patterns of Basal and Squamous Cell Carcinoma in Polycythemia Vera and Essential Thrombocythemia 真性红细胞增多症和原发性血小板增多症中基底细胞癌和鳞状细胞癌的纵向分布模式差异

American Journal of Hematology

IF9.9

2026-05-29

OAAI

Giuseppe G. Loscocco; Naseema Gangat; Paola Guglielmelli; Animesh Pardanani; Alessandro M. Vannucchi; Ayalew Tefferi

Myeloproliferative neoplasms with clinically relevant paroxysmal nocturnal hemoglobinuria: clinical correlations and outcomes 临床相关阵发性睡眠性血红蛋白尿症伴骨髓增殖性肿瘤：临床相关性及预后

Haematologica

IF7.9

2026-05-01

PREAI

Faldu, Priyansh; Abdelaziz, Rania; Yousuf, Muhammad; Pardanani, Animesh; Patnaik, Mrinal; Tefferi, Ayalew; Gangat, Naseema

Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities 真性红细胞增多症和原发性血小板增多症中的自身免疫和炎症性疾病：对疾病结局和合并症的影响

American Journal of Hematology

IF9.9

2026-04-17

OAAI

Giuseppe G. Loscocco; Fnu Aperna; Moazah Iftikhar; Priyansh Faldu; Masooma S. Rana; Animesh Pardanani; Paola Guglielmelli; Alessandro M. Vannucchi; Naseema Gangat; Ayalew Tefferi

CMML2AML: machine-learning discovery of co-mutations and specific single mutations predictive of blast transformation in chronic myelomonocytic leukemia CMML2AML：机器学习发现与慢性骨髓单核细胞白血病blast transformation相关的共突变和特异性单突变

Blood Cancer Journal

IF11.6

2026-04-12

OAAI

Saubia Fathima; Lior Rokach; Muhammad Yousuf; Priyansh Faldu; Ali Alsugair; Clifford Csizmar; Merry Nakhleh; Abhishek A. Mangaonkar; Animesh Pardanani; Luca Lanino; Alessia Campagna; Giulia Maggioni; Noushin Farnoud; Raajit Rampal; Kaaren K. Reichard; Rong He; Naseema Gangat; Mrinal M. Patnaik; Matteo G. Della Porta; Ayalew Tefferi

CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients CPX-351（脂质体阿糖胞苷和柔红霉素）与维奈克拉联合表观遗传药物疗法在初诊急性髓系白血病中的比较：一项涉及600例梅奥诊所患者的回顾性比较研究

Blood Cancer Journal

IF11.6

2026-04-06

OAAI

Saubia Fathima; Lior Rokach; Nour Ghosoun; Mahsa Rezasoltani; Rimal Ilyas; Ali Alsugair; Kristen McCullough; Maymona Abdelmagid; Aref Al-Kali; Hassan B. Alkhateeb; Kebede H. Begna; Abhishek A. Mangaonkar; Aasiya Matin; Antoine N. Saliba; Mehrdad Hefazi Torghabeh; Mark R. Litzow; William Hogan; Mithun Shah; Mrinal M. Patnaik; Animesh Pardanani; Talha Badar; Hemant Murthy; James Foran; Jeanne Palmer; Nathan Punwani; Lisa Sproat; Nandita Khera; Cecilia Arana Yi; Ayalew Tefferi; Naseema Gangat

One vs. 2 vs. ≥3 TET2 mutations in chronic myelomonocytic leukemia: co-mutation patterns and prognostic relevance in the context of contemporary prognostic models including BLAST-mol and CPSS-mol 慢性髓单核细胞白血病患者中1个、2个或≥3个TET2突变的比较：在包括BLAST-mol和CPSS-mol在内的当代预后模型背景下，探讨共突变模式及预后相关性

Blood Cancer Journal

IF11.6

2026-04-04

OAAI

Muhammad Yousuf; Saubia Fathima; Ali Khalid A. Alsugair; Samuel J. Wu; Maymona G. Abdelmagid; Shraddha P. Patel; Priyansh C. Faldu; Rania M. Abdelaziz; Clifford M. Csizmar; Abhishek A. Mangaonkar; Cinthya J. Zepeda Mendoza; Kaaren K. Reichard; David S. Viswanatha; Rong He; Animesh Pardanani; Naseema Gangat; Mrinal S. Patnaik; Ayalew Tefferi

Clinical Experience With Venetoclax-Based Combinations for Relapsed/Refractory or MRD-Positive NPM1-Mutated Acute Myeloid Leukemia 基于Venetoclax的联合方案在复发/难治或MRD阳性NPM1突变急性髓系白血病中的临床经验

American Journal of Hematology

IF9.9

2026-04-01

OAAI

Matteo Piccini; Naseema Gangat; Francesco Mannelli; Barbara Scappini; Gaia Ciolli; Francesca Crupi; Andrea Pasquini; Jessica Caroprese; Giorgio Cannetti; Chiara Lucarelli; Silvia Querceto; Giada Rotunno; Fabiana Pancani; Niccolò Bartalucci; Paola Guglielmelli; Ayalew Tefferi; Alessandro Maria Vannucchi

TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent TP53突变和循环 blasts ≥20% 是接受一线维奈克拉联合去甲基化药物治疗加速期/原始细胞期骨髓增殖性肿瘤患者生存的主要决定因素

American Journal of Hematology

IF9.9

2026-02-18

OAAI

Naseema Gangat; Momna Warraich; Sudhesh Kumar; Mahnoor Fatima; Kristen McCullough; Kebede H. Begna; Aref Al-Kali; Mrinal M. Patnaik; William J. Hogan; Abhishek Mangaonkar; Antoine N. Saliba; Mehrdad Hefazi Torghabeh; Hassan Alkhateeb; Mithun V. Shah; James M. Foran; Talha Badar; Jeanne M. Palmer; Cecilia Arana Yi; Animesh Pardanani; Ayalew Tefferi

NFκB/IL-6/JAK2/STAT axis in myelofibrosis is a key vulnerability that is targetable and relevant to JAK2 inhibitor treatment resistance 骨髓纤维化中的NFκB/IL-6/JAK2/STAT轴是一个可靶向的关键易损点，与JAK2抑制剂治疗耐药性相关。

Blood Cancer Journal

IF11.6

2026-01-12

OAAI

Huiqin Bian; Naseema Gangat; Na Shen; Jiuxia Pang; David Wald; William Tse; Ayalew Tefferi; Fei Yan; Shujun Liu

Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome 三阴性原发性骨髓纤维化：表型、基因型和预后的比较分析

Blood Cancer Journal

IF11.6

2026-01-05

OAAI

Yassin A. Bashir; Ahmed A. Abdelrheem; Maymona Abdelmagid; Kaaren K. Reichard; Rong He; Cinthya J. Zepeda Mendoza; Animesh Pardanani; Naseema Gangat; Ayalew Tefferi

Treatment-relevant misdiagnosis of autoimmune myelofibrosis 与治疗相关的自身免疫性骨髓纤维化误诊

HAEMATOLOGICA

IF7.9

2025-12-01

OAAI

Gangat, Naseema; Reichard, Kaaren K.; Orazi, Attilio; Viswanatha, David S.; Hanson, Curtis; Tefferi, Ayalew

CSF3R mutations and variants in myeloid neoplasms: associated phenotypes, co-mutations, and survival trends Bolarinwa, A.; Szuber, N.; He, R.; Pardanani, A.; Gangat, N.; Tefferi, A. CSF3R突变和变异在髓系肿瘤中的研究：相关表型、共突变及生存趋势。Haematologica 2025. [Google Scholar] [CrossRef]

HAEMATOLOGICA

IF7.9

2025-12-01

OAAI

Bolarinwa, Abiola; Szuber, Natasha; He, Rong; Pardanani, Animesh; Gangat, Naseema; Tefferi, Ayalew

Plasmacytoid Dendritic Cell-Expansion in Acute Myeloid Leukemia (pDC‑AML): a Review of Clinicopathologic Features, Genetics, and Outcomes 浆细胞样树突状细胞在急性髓系白血病中的扩增（pDC-AML）：临床病理特征、遗传学及预后的综述

Current Hematologic Malignancy Reports

IF3.3

2025-11-05

PREAI

Azza E. A. Abdalla; Mohammed Abdulgayoom; Abdulrahman F. Al-Mashdali; Firyal Ibrahim; Naseema Gangat; Shehab F. Mohamed

Low (0.1% to ≤ 1%) or Very Low (0.06% to < 0.1%) JAK2V617F Allele Burden in Routine Testing: Clinical Correlates and Clonal Trajectory 低（0.1%至≤1%）或极低（0.06%至<0.1%）JAK2V617F等位基因负荷在常规检测中的临床相关性及克隆轨迹

American Journal of Hematology

IF9.9

2025-11-03

OAAI

Ruah Alyamany; Ahmed Alnughmush; Oleksandr Klymenko; Mohammad Alhousani; Animesh Pardanani; Paul L. Ollila; David S. Viswanatha; Naseema Gangat; Rong He; Ayalew Tefferi

研究方向